A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Public ClinicalTrials.gov record NCT02431208. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT). Cycle length will be 21 days in Cohorts A to C and 28 days in Cohorts D to F.
Study identification
- NCT ID
- NCT02431208
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 85 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Drug
- Daratumumab Drug
- Lenalidomide Drug
- Pomalidomide Drug
- Dexamethasone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 22, 2015 (Actual)
- Primary completion
- Mar 19, 2021 (Actual)
- Completion
- Mar 19, 2021 (Actual)
- Last update posted
- Apr 2, 2021
2015 – 2021
United States locations
- U.S. sites
- 31
- U.S. states
- 22
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| University Of Arkansas | Little Rock | Arkansas | 72205 | — |
| Scripps Clinic Torrey Pines | La Jolla | California | 92037 | — |
| UC Davis; Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| University of California, San Francisco | San Francisco | California | 94116 | — |
| Yale University | New Haven | Connecticut | 06511 | — |
| Mayo Clinic Hospital - Florida | Jacksonville | Florida | 32224 | — |
| Emory Univ Winship Cancer Inst | Atlanta | Georgia | 30322 | — |
| Loyola University Med Center | Maywood | Illinois | 60153 | — |
| Indiana University Health; Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Indiana University Department of Medicine; IU Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Louisville | Louisville | Kentucky | 40202-1798 | — |
| University of Maryland School of Medicine | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Med Ctr; Hem/Onc | Boston | Massachusetts | 02215 | — |
| Univ of Michigan Medical Ctr | Ann Arbor | Michigan | 48109-0718 | — |
| Karmanos Cancer Institute. | Detroit | Michigan | 48201 | — |
| Henry Ford Hospital; Hematology Oncology | Detroit | Michigan | 48202 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89014 | — |
| Mount SInai Medical Center | New York | New York | 10029 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| UNC Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44915 | — |
| University of Oklahoma Health Sciences Center; Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Lifespan Cancer Institute | Providence | Rhode Island | 02905 | — |
| Medical University of South Carolina; Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Texas Oncology-Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| UT Southwestern MC at Dallas | Dallas | Texas | 75390 | — |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02431208, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2021 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02431208 live on ClinicalTrials.gov.